Combining Endocannabinoid Boosters With Anti-Inflammatory Drugs Reduced Post-Surgical Pain in Mice

MAGL inhibitors (JZL184 and MJN110) reduced mechanical pain sensitivity after hindpaw surgery in mice. The pain relief worked through CB2 receptors, not CB1. Importantly, combining doses of JZL184 and diclofenac that were individually too low to reduce pain produced significant relief when given together. Repeated JZL184 administration did not lead to tolerance.

Male and female C57BL/6J mice underwent hindpaw incision surgery. Mechanical allodynia was measured 24 hours post-surgery using von Frey filaments. Dose-response curves were established for MAGL inhibitors and diclofenac. CB1 and CB2 antagonists were used to identify receptor mechanisms. Repeated dosing tested for tolerance. Hindpaw cytokines were measured via multiplex ELISA.

Post-surgical pain management often relies on opioids, which carry addiction risks. This study demonstrates that boosting the body's own endocannabinoids can reduce pain, and that combining this approach with common anti-inflammatory drugs could allow lower doses of each, potentially reducing side effects.

The finding that endocannabinoid-based pain relief works through CB2 (not CB1) receptors in this model is significant because CB2 activation avoids the psychoactive effects associated with CB1. The additive interaction with NSAIDs suggests a practical combination strategy that could reduce reliance on opioids after surgery.

Animal study; translation to humans uncertain. Hindpaw incision is a simplified model of surgical pain. MAGL inhibition did not reduce inflammatory cytokines despite behavioral pain relief, suggesting the mechanism may be primarily neural rather than anti-inflammatory. Both sexes used but sex-specific analysis not detailed.